Artiva Biotherapeutics, INC 8-K filings

Artiva Biotherapeutics announced its 2026 annual meeting of stockholders will be held on September 8, 2026, with deadlines for stockholder proposals and nominations set for August 1, 2026.

Artiva Biotherapeutics has appointed Diego Miralles as President and Head of R&D, while CFO Thad Huston departs.

Artiva Biotherapeutics, Inc. has entered into an underwriting agreement to raise approximately $300 million through a public offering of common stock and pre-funded warrants.

Artiva Biotherapeutics announced first-quarter 2026 financial results and highlighted positive initial clinical data for its AlloNK therapy in autoimmune diseases, alongside FDA alignment for a Phase 3 trial in rheumatoid arthritis.

Artiva Biotherapeutics, Inc. announced the appointment of Thad Huston, a seasoned finance and operations executive, as its new Chief Financial Officer, effective February 18, 2026.

Artiva Biotherapeutics, Inc. announced the appointment of Elaine Sorg, a seasoned pharmaceutical executive, as a Class I director to its Board.

Artiva Biotherapeutics implemented an option for RSU exchange program to enhance employee retention and align interests with stockholders.

Artiva Biotherapeutics announced positive initial safety and translational data for AlloNK in autoimmune diseases, demonstrating deep B-cell depletion and good tolerability in outpatient settings.

Artiva Biotherapeutics announced its third-quarter 2025 financial results, highlighting progress with its lead program AlloNK, including FDA Fast Track Designation for refractory rheumatoid arthritis and an extended cash runway into Q2 2027.

Artiva Biotherapeutics announced its second quarter 2025 financial results, highlighting progress in its AlloNK clinical trials for autoimmune diseases and a cash runway into Q2 2027.

Artiva Biotherapeutics, Inc. announced that its stockholders approved an amendment to the 2024 Equity Incentive Plan, increasing authorized shares by 1,214,580, alongside the election of a Class I Director and ratification of its independent accounting firm at the 2025 Annual Meeting.

Artiva Biotherapeutics announces Q1 2025 financial results, highlighting IND clearance and initiation of a global basket trial for AlloNK in refractory autoimmune diseases, along with a cash runway extended into Q2 2027.

Artiva Biotherapeutics announced its full year 2024 financial results, highlighting a strengthened balance sheet and progress in its AlloNK program.

Artiva Biotherapeutics appoints Daniel Baker, Ph.D., to its Board of Directors and Clinical Strategy Committee, effective January 28, 2025.

Artiva Biotherapeutics announced its third quarter 2024 financial results, highlighted by a strong cash position of $199.6 million and the expansion of its Board of Directors.

Artiva Biotherapeutics has appointed Alison Moore, Ph.D., as a Class III director and member of the Technical Operations Committee, effective October 21, 2024.

Artiva Biotherapeutics announced its second quarter 2024 financial results, highlighted by a successful IPO and progress in clinical trials for its AlloNK cell therapy.

Artiva Biotherapeutics finalized its initial public offering on July 22, 2024, concurrently amending its certificate of incorporation and bylaws.